Although somatic SHP2 mutations are rare in solid tumors [47], aberrant activation of upstream RTKs, such as the overexpression of HER2 in breast cancer [48] and EGFR in colon cancer [49], has been shown to activate SHP2 to promote cancer development, progression, and resistance to targeted therapies. The gene discussed is PTPN11; the disease is breast cancer.